STOCK TITAN

Regencell Bioscience Holdings (RGC) SEC Filings

RGC NASDAQ

Regencell Bioscience Holdings Limited filings document a Cayman Islands foreign private issuer developing Traditional Chinese Medicine candidates for ADHD, ASD and infectious-disease applications. Its Form 6-K reports include unaudited condensed consolidated interim financial statements, management financial results and disclosure incorporated by reference into registration materials.

The filing record also covers ordinary-share capital matters, including registration statements, prospectus supplements, sales agreements and employee and director lock-up undertakings tied to options and shares. Governance disclosures address board and committee changes, while auditor-change filings describe independent registered public accounting firm appointments, audit history and going-concern-related audit-report language.

Rhea-AI Summary

Regencell Bioscience Holdings Ltd (RGC) director William Wing Yan Lo exercised options for 36,001 ordinary shares on November 17, 2026, at an exercise price of $0.84 per share. The price reflects the issuer’s share splits since the options were granted. After the exercise, he directly held 485,629 ordinary shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
insider
-
Rhea-AI Summary

Regencell Bioscience Holdings Ltd (RGC) director Wing Yan William Lo reported a proposed sale of 36,001 ordinary shares, with an aggregate market value of US$169,924.72. The proposed sale date is November 18, 2026; the value is based on the November 16, 2026 closing price of US$4.72 per share.

Lo acquired the shares on November 17, 2026 by exercising stock options under the issuer’s 2021 share option plan. Regencell had 495,884,376 ordinary shares issued and outstanding as of October 7, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.60%
Tags
other
-
Rhea-AI Summary

Regencell Bioscience Holdings Limited reported a net loss of $11.70 million for fiscal 2026, compared with $3.58 million for fiscal 2025. It has generated no revenue from product sales. As of the annual report date, its standardized traditional Chinese medicine (TCM) formula candidates for ADHD and autism spectrum disorder remained in development; its second efficacy trial in Hong Kong was ongoing, and the company had not applied for regulatory approval.

Regencell expects to continue incurring increasing operating losses and may need substantial additional financing to implement its business plan. It had 495,884,376 ordinary shares issued and outstanding as of June 30, 2026. As of the annual report date, Chairman, Director and Chief Executive Officer Yat-Gai Au was deemed the beneficial owner of 437,896,116 ordinary shares held by a company wholly owned by him and his spouse; the ownership table reports 88.3% of votes held. The company said a U.S. Department of Justice investigation into trading in its ordinary shares was ongoing; it is cooperating, cannot predict the resolution, and expects significant related legal costs. Regencell does not anticipate declaring or paying cash dividends in the foreseeable future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
annual report
Rhea-AI Summary

Regencell Bioscience Holdings Ltd director Dr. William Wing Yan Lo reported a disposition of stock options back to the company. On May 27, 2026, the issuer repurchased options covering 70,600 ordinary shares at $15.00 per option, which had an exercise price of $0.84 per share. Following this transaction, Dr. Lo held 521,630 stock options directly in the same security class. The filing characterizes the event as a disposition to the issuer rather than an open-market trade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
insider
-
Rhea-AI Summary

Regencell Bioscience Holdings Ltd director HUI EVANA YEE WAH reported a disposition of stock options back to the company. On May 27, 2026, the issuer repurchased options to purchase 19,000 ordinary shares at $15.00 per option under an Option Repurchase Agreement.

The repurchased options had an exercise price of $0.25 per share. Following this issuer disposition, the reporting person is shown with 573,230 shares related to this security, indicating she retains a substantial position after the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
insider
-
Rhea-AI Summary

Regencell Bioscience Holdings Limited closed a registered direct offering of ordinary shares, raising approximately $20.0 million in gross proceeds. The deal was led by a new fundamental institutional investor that contributed $19 million, with additional participation from Univest Securities, LLC.

The company sold an aggregate of 985,222 ordinary shares at $20.30 per share under a previously filed automatic shelf registration statement on Form F-3. Univest acted as sole placement agent. Regencell describes itself as an early-stage bioscience company focused on Traditional Chinese Medicine treatments for ADHD and autism spectrum disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
current report
Rhea-AI Summary

Regencell Bioscience Holdings Limited is conducting a registered direct offering of 985,222 Ordinary Shares at $20.30 per share. The offering is being sold directly to certain investors pursuant to a securities purchase agreement and a prospectus supplement dated May 19, 2026. The Placement Agent, Univest Securities, LLC, agreed to purchase 49,262 Ordinary Shares for $1.0 million and will receive cash fees equal to 6.5% of aggregate gross proceeds. Net proceeds to the company are expected to be approximately $18.4 million, intended for working capital and general corporate purposes. Shares outstanding were 494,488,908 as of December 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
prospectus
-
Rhea-AI Summary

Regencell Bioscience Holdings Limited has entered into a definitive agreement for a registered direct offering of 985,222 ordinary shares at $20.30 per share. The company expects aggregate gross proceeds of approximately $20.0 million, led by a $19 million investment from a new fundamental institutional investor, with additional participation from Univest Securities, LLC.

The transaction is expected to close on or about May 20, 2026, subject to customary closing conditions, with Univest acting as sole placement agent. The offering is being made under an effective shelf registration statement on Form F-3, with a related prospectus supplement and accompanying prospectus to be filed and made available through the SEC and Univest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
current report
-
Rhea-AI Summary

Regencell Bioscience Holdings Limited has entered a definitive agreement for a registered direct offering of 985,222 ordinary shares at $20.30 per share. The company expects aggregate gross proceeds of about $20.0 million from this primary share sale.

The offering is led by a new fundamental institutional investor committing $19 million, with additional participation from Univest Securities, LLC, which acts as sole placement agent. The transaction is expected to close on or about May 20, 2026, subject to customary closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.66%
Tags
current report

FAQ

How many Regencell Bioscience Holdings (RGC) SEC filings are available on StockTitan?

StockTitan tracks 26 SEC filings for Regencell Bioscience Holdings (RGC), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Regencell Bioscience Holdings (RGC)?

The most recent SEC filing for Regencell Bioscience Holdings (RGC) was filed on November 17, 2026.